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On April 13, 2000, the Canadian Parliament enacted by Royal Assent the Personal
Information Protection and Electronic Documents Act (PIPEDA).1 The Act requires
private organizations to comply with a code of "fair information practice," which man-
dates individual consent for the collection, use, and disclosure of personal information.2
PIPEDA complements the Federal Privacy Act, which places similar obligations on
government institutions.3 On January 1, 2002, the Act began to apply to personal infor-
mation (including personal health information) collected, used, or disclosed by a federal
work, undertaking, or business, and personal information (including personal health
information) disclosed by any organization for consideration outside the province in
which it was collected.
This article describes PIPEDA and explains how it will apply to pharmaceutical com-
panies and device manufacturers operating in Canada. Section I provides an overview
of privacy legislation in Canada. Section II discusses the new Act's scope, the obliga-
tions it imposes, and the rights it creates. Section III discusses enforcement of the Act.
Section IV considers the relationship between PIPEDA and other privacy laws in Canada,
the European Union (EU), and the United States. Finally, Section V describes the transi-
tion periods before the Act is fully effective.
It is not entirely clear how PIPEDA will affect pharmaceutical and device manufactur-
ers in Canada. PIPEDA is based on a privacy code drafted by private industry. The
healthcare sector was not a significant participant in the drafting of that code, and the
statute, therefore, is not tailored to address the specific concerns of pharmaceutical and
device manufacturers. Also, the new Privacy Commissioner, who lacks a medical or
scientific background, has said little about how he intends to apply the legislation to the
healthcare sector. This article offers some speculation. Guidance and decisions issued
in the next year may resolve some of the uncertainties.
' Ms. King is Assistant General Counsel at PhRMA, Washington, D.C. When this article was
written, she was an Associate with the law firm of Covington & Burling, Washington, D.C.
Mr. Fuson is an Associate with the law firm of Covington & Burling, Washington, D.C.
1999-2000 S.C. 2000, ch. 5 (Can.). Part I of the Act (Personal Information Protection)
establishes rules governing the collection, use, and disclosure of personal information in the private
sector. Part 2 (Electronic Documents) addresses the use of electronic alternatives to paper records.
This article addresses only Part 1.
I Bruce Phillips, Privacy Commissioner of Canada, The Evolution of Canada's Privacy Laws, Address
to the Canadian Bar Association-Ontario Institute 2000 (Jan. 28, 2000), available at http://
www.privcom.gc.ca/speech/archive/02_05._a.000128_e.asp (last visited June 19, 2002). According to its
statement of scope, the Act establishes rules governing "the collection, use, and disclosure" of informa-
tion. The Model Code on which it is based and which is incorporated as its "Schedule 1" distinguishes
between "use" and "retention." The statute plainly applies to both. This article uses the "collect, use, and
disclose" convention except where the use of "retention" will clarify the discussion.
I Bruce Phillips, Privacy Commissioner of Canada, 1999 Annual Report of the Privacy Com-
missioner (July 1999), available at http://www.privcom.gc.ca/information/ar/02_04_07_e.asp (last
visited June 19, 2002).
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I. BACKGROUND
A. Prior Privacy Legislation
On July 1, 1983, the Federal Privacy Act went into effect. The Privacy Act protects
personal information collected and held by over 150 designated public agencies and
institutions.4 These agencies and institutions vary in size and scope, and range from the
Departments of State and Finance to the Northwest Territories Water Board.' The Pri-
vacy Act prohibits each from collecting personal information not related directly to its
operating programs or activities,6 and from making unrelated uses or disclosures of
such information without the individual's consent.' These agencies and institutions
must also provide individual data subjects access to their personal information stored in
government data banks.'
The Privacy Act also established the Office of the Privacy Commissioner.9 The Pri-
vacy Commissioner is appointed by the Governor in Council and approved by Parlia-
ment,"0 and is charged with investigating complaints from individuals about the
government's use and handling of their personal information.
Several Canadian provinces also have passed privacy legislation. The most compre-
hensive provincial legislation is Quebec's Personal Information Protection Act, passed
in 1994, which governs the collection, use, and disclosure of personal information by
private organizations in Quebec."l Other provinces, including Alberta and Manitoba,
have passed healthsector-specific statutes limiting the collection, use, and disclosure
of personal information by healthcare professionals and facilities.'2
B. The CSA Model Code for the Protection of Personal Information
PIPEDA's core provisions were based on the Model Code for the Protection of Per-
sonal Information, approved in 1996 by the Canadian Standards Association. 3 The
Model Code describes ten interrelated principles deemed essential for the protection of
personal privacy. They are:
0 Accountability
An organization is responsible for personal information under its
control and shall designate an individual or individuals who are ac-
4 Office of the Privacy Commissioner, Privacy Legislation in Canada: Two Federal Laws,
available at http://www.privcom.gc.ca/fs-fi/fs200l-O2-e.asp (last visited June 19, 2002).
Privacy Act, Schedule (§ 3).
6 Id. Collection, Retention and Disposal of Personal Information.
Id. Protection of Personal Information.
Id. Access to Personal Information.
Id. Office of the Privacy Commissioner.
tO The Office is currently held by George Radwanski, a former journalist. He was approved by
Parliament in October 2000 for a seven-year term. See Privacy Commissioner of Canada, About the
Office of the Privacy Commissioner, available at http://www.privcom.gc.ca/au-e.asp (last visited
June 19, 2002).
" R.S.Q. Ch. P-39.1, An Act Respecting the Protection of Personal Information in the Private
Sector.
'2 Alberta Health and Wellness, available at http://www.health.gov.ab.ca (last visited June 19,
2002); Manitoba Access and Privacy Division, available at http:www.ombudsman.mb.ca (last visited
June 19, 2002).
13 The Canadian Standards Association is an independent not-for-profit organization of business,
industry, government, and consumer groups. See The Canadian Standards Association Homepage,
available at http://www.csa.ca (last visited June 19, 2002).
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countable for the organization's compliance with the following prin-
ciples.'4
• Identified Purposes
The purposes for which personal information is collected shall be
identified by the organization at or before the time the information is
collected. '
" Consent
The knowledge and consent of the individual are required for the
collection, use, or disclosure of personal information, except where
inappropriate."
• Limited Collection
The collection of personal information shall be limited to that which is
necessary for the purposes identified by the organization. Informa-
tion shall be collected by fair and lawful means. 7
" Limited Use, Disclosure, and Retention
Personal information shall not be used or disclosed for purposes other
than those for which it was collected, except with the consent of the
individual or as required by law. Personal information shall be retained
only as long as necessary for the fulfillment of those purposes. 8
" Accuracy
Personal information shall be as accurate, complete, and up-to-date
as is necessary for the purposes for which it is to be used. 9
* Security
Personal information shall be protected by security safeguards ap-
propriate to the sensitivity of the information.20
* Openness
An organization shall make readily available to individuals specific
information about its policies and practices relating to the manage-
ment of personal information. 2'
'C CSA Model Code Principle 1-Accountability; PIPEDA Schedule 1, § 4.1.
'5 CSA Model Code Principle 2-dentifying Purposes; PIPEDA Schedule 1, § 4.2.
' CSA Model Code Principle 3--Consent; PIPEDA Schedule 1, § 4.3.
CSA Model Code Principle 4-Limiting Collection; PIPEDA Schedule 1, § 4.4.
Is CSA Model Code Principle 5-Limiting Use, Disclosure, and Retention; PIPEDA Schedule 1,
§ 4.5.
19 CSA Model Code Principle 6-Accuracy; PIPEDA Schedule 1, § 4.6.
20 CSA Model Code Principle 7-Safeguards; PIPEDA Schedule 1, § 4.7.
21 CSA Model Code Principle 8-Openness; PIPEDA Schedule 1, § 4.8.
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* Right of Access
Upon request, an individual shall be informed of the existence, use,
and disclosure of his or her personal information and shall be given
access to that information. An individual shall be able to challenge
the accuracy and completeness of the information and have it
amended as appropriate.22
* Compliance
An individual shall be able to address a challenge concerning compli-
ance with the above principles to the designated individual or indi-
viduals accountable for the organization's compliance.
2 1
The Canadian Parliament incorporated the ten Model Code principles, with only
minor modifications, directly into the Act.24
C. Enactment of PIPEDA
An earlier version of the Act was introduced in October 1998 as Bill C-54 but the
House failed to take final action on it before recessing. The Act was reintroduced in
October 1999 as Bill C-6 and this time, the House took prompt action and passed the bill,
sending it to the Senate.
Responding to the health sector's concern that it would need extra time to implement
appropriate policies and procedures to protect personal health information, the Senate
added an amendment to delay the bill's application to personal health information by
one year.25 Health sector representatives pointed out that the health sector had not
participated in the drafting of the Model Code on which the proposed privacy legisla-
tion was based. The resulting code was designed primarily to encourage electronic
commerce and did not focus on privacy issues that might be significant in the medical
context. The Canadian Medical Association (CMA) was quick to note that "the world of
healthcare [is] very different from that of commerce and consequently require[s] distinct
rules. ' 26 It criticized the Act's failure to take into account any of the health-sector
specific modifications added in the CMA's version of the Model Code. 27
The House passed the Act without further changes. Although it adopted the Senate's
amendment delaying the Act's application to personal health information, it did not add
a separate code to govern that information. 28
22 CSA Model Code Principle 9-Individual Access; PIPEDA Schedule 1, § 4.9.
23 CSA Model Code Principle 10-Challenging Compliance; PIPEDA Schedule 1, § 4.10.
24 Second Report of the Standing Senate Committee on Social Affairs, Science and Technology
(Dec. 6, 1999); Phillips, 1999 Annual Report of the Privacy Commissioner, supra note 3.
23 See John Cannis, Parliamentary Secretary to the Minister of Industry, House of Commons
Debate (Feb. 14, 2000), available at http://www.privcom.gc.ca./information/0206corn000214.e.asp
(last visited June 19, 2002) (commenting on the Senate amendments).
26 Canadian Medical Association, Listening to Our Patient's Concerns: Comments on Bill C-54,
Submitted to the House Standing Committee on Industry (Mar. 18, 1999), available at http://
www.cma.calcmalcommon/displayPage.do?pageld=/StaticContentHTML/NO/12/where-we-stand/
political/1999/03-18/index.htm (last visited June 19, 2002).
27 Id. The CMA's Health Information Privacy Code granted patients strict control over personal
health information, without the exceptions provided in the Act for "expediency, practicality, public
good, research, offence investigation, historic importance and artistic purpose." Id.
I' A separate code was suggested in the House debate. See Keith Martin, House of Commons Debate
(Feb. 14, 2000), available at http://www.privcom.gc.ca./information/02_06_com_000214.e.asp (last
visited June 19, 2002) (calling for a code of conduct limiting access to personal health information).
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D. Interpretation of PIPEDA
Parliament's decision to use the Model Code as separate provisions of this legisla-
tion creates some interpretive problems for affected parties. The Model Code is inher-
ently vague-officials at the Office of the Privacy Commissioner concede this point29-
and the Privacy Commissioner has significant discretion in interpreting its provisions.
His statements in informal guidance on the Office's web site and in speeches provide
some insight into how he will apply PIPEDA to the healthcare sector. In the only deci-
sion to date that related to the healthcare industry, the Privacy Commissioner indicated
his willingness to take into account the practical business implications of his decisions.
In that decision, the Commissioner rejected a complaint filed by physicians alleging that
IMS Health Canada sold information about their prescribing habits without their con-
sent. IMS collected prescription information such as drug identification numbers, insur-
ance information, the patient's gender and date of birth, as well as the name and identi-
fication number of the prescribing physician. The Commissioner concluded that this
information was not personal information, but rather more akin to work product. To find
otherwise, he wrote, "would have the effect of precluding many kinds of legitimate
commercial consumer reporting."30
Because its provisions formed the basis of PIPEDA, the CSA Model Code and ac-
companying commentary provide additional insight about the Act's likely application.
Also, industry groups like the CMA used the Model Code to develop sector-specific
privacy protection codes. The CMA Health Information Privacy Code, approved in
1998, modifies the ten Model Code principles to specifically promote "the privacy of
patients, the confidentiality and security of their health information and the trust and
integrity of the therapeutic relationship." It recognizes the "special nature of health
information," including "its highly sensitive nature, the circumstances of vulnerability
and trust under which it is confided or collected, and the fiduciary duties of health
professionals in relation to this information."'" Although PIPEDA did not incorporate
sector-specific rules, the Privacy Commissioner may look to this industry code for
guidance when evaluating whether a pharmaceutical or device manufacturer has taken
reasonable steps to protect personal information.
Interpretation of the Act is further complicated by the fact that it is comprised of both
mandatory provisions an organization must follow-"[o]rganizations shall put proce-
dures in place to receive and respond to complaints"-and recommendations an organi-
zation may adopt to enhance privacy protections and ensure compliance-"[t]he com-
plaint procedures should be easily accessible and simple to use."32 This distinction may
be of little practical import, however, because the Commissioner may audit an organiza-
tion he believes is not following a recommendation.3
29 Anne Rooke, The New Wave of Privacy Protection in Canada, Address to the FIPA Confer-
ence (Mar. 9, 2000), available at http://www.privcom.gc.ca/speech/02-05-a_000309_e.asp (last
visited June 19, 2002) ("As well intentioned as the CSA Model Privacy Code is, it is not a watertight
legal text. Settling in its interpretation will not be easy.").
30 Office of the Privacy Commissioner, Privacy Commissioner Releases His Finding on the
Prescribing Patterns of Doctors (Oct. 2, 2001), available at http:www.privcom.gc.ca/media/an/
wn_011002e.asp (last visited June 19, 2002).
31 CMA Health Information Privacy Code, available at http://www.cma.ca/cma/common/
DisplayPage.do?pageld=/StaticContent/HTMLNO/12/wherewe-standl1998/09-16.htm (last visited
June 19, 2002).
32 PIPEDA Schedule 1, § 4.10.2 (emphasis added). See also id. § 5(2) ('The word 'should'
indicates a recommendation and does not impose an obligation.").
33 Id. § 18(1).
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II. RIGHTS AND OBLIGATIONS UNDER THE PERSONAL INFORMATION
PROTECTION AND ELECTRONIC DOCUMENTS ACT
A. Scope of the Act
The Act requires "every organization" that "collects, uses or discloses" personal
information "in the course of commercial activities" to take steps to protect individual
privacy. 4 This requirement encompasses four basic points.
1. Every Organization
First, the Act applies to "every organization." An "organization" is an association, a
partnership, a person, or a trade union. 5 It includes both "brick-and-mortar" and e-
commerce businesses, and would clearly extend to physicians, pharmacies, and phar-
maceutical and device manufacturers.36
2. Collection, Use, and Disclosure
Second, the Act applies to the collection, use, and disclosure of personal informa-
tion.37 "Use" is the "treatment and handling of personal information within an organiza-
tion."3 According to the Model Code, this occurs "any time data about an identifiable
individual is accessed, manipulated, altered, deleted, or destroyed within the organiza-
tion."39 This would include the processing of payroll information about employees, for
example, as well as the manipulation of data collected in a clinical trial. In contrast,
"disclosure" involves the transfer of data outside the organization.4" This would pre-
sumably include the transfer of clinical trial data or adverse event data pertaining to a
marketed product to a foreign regulatory agency like the U.S. Food and Drug Adminis-
tration (FDA).
The Privacy Commissioner emphasizes that collection, use, and disclosure are sepa-
rate events.41 For example, consent to collect names and addresses for billing purposes
(a use) does not indicate consent to transfer that data to third-party advertisers (an
unrelated disclosure). Analogously, consent to the collection and analysis of one's
basic health information for epidemiological purposes does not contribute consent to
the sale of that information by the collecting company to a third party for direct-to-
consumer marketing of healthcare products. The organization must treat these activities
as separate and obtain consent for each.
3 Id. § 4(1).
35 Id. § 2(1).
36 Office of the Privacy Commissioner, Backgrounder: The Personal Information Protection
and Electronic Documents Act, available at http://www.privcom.gc.ca/information/02-06-07-e.asp
(last visited June 19, 2002).
17 PIPEDA § 4(l)(a).
38 OFFICE OF THE PRIVACY COMMISSIONER OF CANAlDA, YOUR PRIVACY RFSI)NSIBIIITIFS: A GUIDE FOR BUsN-ESSES
AND ORGANIZATIONS 2 (2001) [hereinafter GUIDE FOR BUSINESSES].
3 9 CANADIAN STANDARDs ASSOCIATION, MAKING THE CSA PRIVACY CODE WORK FOR YOU 10 (1996) [herein-
after CSA WORKBOOK].
o Id.; see also GUIDE FOR BUsiNrssEs, supra note 38, at 2.
George Radwanski, Privacy Commissioner of Canada, Address to the Institute of Canadian
Advertising (Feb. 27, 2001), available at http://www.privcom.gc.ca/speech/02-05_a_010227_e.asp
(last visited June 19, 2002).
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3. Personal Information
Third, the Act applies to "personal information," which is "information about an
identifiable individual." Personal information may take many forms. It includes factual
data such as an individual's name, age, identification numbers, income, ethnic origin,
blood type, and genetic data.42 The Commissioner may read this definition even more
broadly to include tissue, blood, and other biological samples. In a recent speech, he
argued that a code protecting the privacy of genetic information "must govern collec-
tion, analysis, retention, and disclosure of genetic material, not just the information
derived from it."'43
Personal information includes subjective data such as an individual's opinions, evalu-
ations, comments, and social status.' It includes recorded data in employee files, credit
records, loan records, medical records, disciplinary records, and records documenting
disputes between a consumer and a merchant. It also includes unrecorded data such as
an individual's oral expression of intent to acquire goods or services or to change jobs.45
a. Identifiable Individual
The Act governs information linked to an "identifiable individual." Data that have
been made anonymous are exempt from the Act and may be used freely within an
organization or disclosed to others outside the organization without the consent of the
individual subject. The Privacy Commissioner has not clarified the meaning of "identi-
fiable" or "anonymous," and no reported Privacy Commissioner decisions address the
topic. If the identity of a data subject is apparent from the data (for instance, if the data
include his name, or perhaps if they include a personal identification number), the
Privacy Commissioner will undoubtedly consider the data subject "identifiable." It is
less certain whether the Privacy Commissioner would consider a data subject to be
"identifiable" if a recipient could, with some effort, identify the data subject through
reference to other publicly-available information. It may be possible to persuade the
Commissioner that data have been made anonymous if it would be extremely difficult
(rather than impossible) to identify individuals. It is also unclear how the Privacy Com-
missioner would treat data that have been key-coded where the key has been separated
from the data (for example, if a principal investigator codes clinical data prior to transfer-
ring the data to the trial sponsor).
b. Personal Health Information
Personal information includes personal health information about an individual,
whether living or deceased.' Personal health information is:
41 George Radwanski, Privacy Commissioner of Canada, Genetic Information and the Right to
Privacy, Address to the UNESCO International Bioethics Committee (Sept. 13, 2001), available at
http://www.privcom.gc.ca/speech/02_05_a_010913e.asp (last visited June 19, 2002) ("Genetic in-
formation is personal health information.").
43 Id.
44 GUIDE FOR BusINEssEs, supra note 38, at 1.
45 The Privacy Commissioner commended Parliament "for building in the flexibility to include
collection of information that is not necessarily recorded" because it "allows individuals to challenge
practices such as putting video cameras in change rooms even when the surveillance is not taped."
Bruce Phillips, Privacy Commissioner of Canada, Comments Before the Standing Committee on
Industry (Mar. 18, 1999), available at http://www.privcom.gc.ca/speech/archive/
02_05a_990318_e.asp (last visited June 19, 2002).
41 Personal health information was excluded from the scope of the Act for the first year of its
implementation.
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" information about the physical or mental health of the individual;
" information about any health service provided to the individual;
" information about the donation by the individual of any body part or any bodily
substance or information derived from the testing or examination of a body part or
bodily substance;
• information collected in the course of providing health services to the individual; or
" information collected incidentally to the provision of health services to the indi-
vidual.47
c. Comparison With HIPAA
The PIPEDA notions of "personal health information" and "identifiable individual"
are consistent with, but more specific than, the definitions of "health information" and
"individually identifiable health information" under the regulations issued by the U.S.
Department of Health and Human Services (DHHS) pursuant to the Health Insurance
Protection and Portability Act (HIPAA).
Under the HIPAA privacy regulations, "health information" is any information that
"relates to the past, present, or future physical or mental health or condition of an indi-
vidual; the provision of health care to an individual; or the past, present, or future payment
for the provision of health care to an individual."'49 Although the U.S. definition is phrased
differently than the Canadian definition, they should extend to the same data.
Health information is individually identifiable in the United States if it "identifies the
individual" or provides "a reasonable basis to believe the information can be used to
identify the individual."5 Conversely, the U.S. privacy regulations do not apply to
information that a covered entity has de-identified. Information is de-identified if it does
not identify the individual and the covered entity has no reasonable basis to believe it
can be used to identify the individual."1
There are two ways in which a covered entity may determine that it has met this
standard. First, a person "with appropriate knowledge and experience applying gener-
ally accepted statistical and scientific principles and methods for rendering information
not individually identifiable" may determine that the risk is "very small" that the infor-
mation could be used by anticipated recipients to identify a subject.52 Second, a covered
entity may strip the information of eighteen enumerated identifiers; if, after having done
so, the covered entity has "no actual knowledge" that the information could be used to
identify a subject, the information is de-identified.5 3 The enumeration of eighteen iden-
tifiers in the U.S. privacy regulations effectively creates a safe harbour that is techni-
cally not available under PIPEDA.
d. Public Information
Publicly-available information is not subject to the consent requirements of the Act.
Accordingly, organizations do not need consent to collect, use, or disclose names,
addresses, and telephone numbers appearing in a telephone directory, if the subscriber
47 PIPEDA § 2(1).
4 Pub. L. No. 104-191, Aug. 21, 1996, 110 Stat. 1936.
0 45 C.F.R. § 160.103.
50 Id. § 164.501.
51 Id. § 164.514.
52 Id. § 164.514(b)(1).
" Enumerated identifiers include: biometric identifiers, full face photographic images, device
identifiers and serial numbers, birth dates, and "any other unique identifying number, characteristic, or
code." Id. § 164.514(b)(2).
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may refuse to have this information appear in the directory. Contact information appear-
ing in a business directory is similarly deemed public and may be collected, used, or
disclosed for purposes related directly to the purpose for which the information appears
in the directory. Personal information in court records is also considered public, as is
information appearing in newspapers or other publications where the individual has
provided the information.54 Personal information collected under statutory authority
and appearing in a public registry (e.g., directors ofcorporations listed under securities
disclosure legislation) is also considered public.
4. Commercial Activity
Finally, the Act applies to "commercial activity," which includes "any particular trans-
action, act or conduct or any regular course of conduct that is of a commercial character."55
Neither the legislative history nor guidance from the Office of the Privacy Commissioner
sheds further light on the phrase's meaning. Pharmaceutical and device manufacturers
collect, analyze, and use personal health information for a variety of commercial purposes,
including the preparation of applications for marketing authorization. This will constitute
use "in the course of commercial activity" under PIPEDA. Accordingly, manufacturers will
be subject to PIPEDA with respect to this personal information.
5. General Exceptions From the Act
PIPEDA does not apply to government organizations that are subject to the Federal
Privacy Act. It does not apply to individuals collecting, using, or disclosing personal
information only for domestic purposes (e.g., for personal address books). It does not
apply to organizations collecting, using, or disclosing personal information only "for
journalistic, artistic or literary purposes."56
The Act also excepts from the requirement of consent for use and disclosure informa-
tion that is used or disclosed "for statistical, or scholarly study or research."57 This excep-
tion applies if 1) the purposes cannot be achieved without using the information, 2) the
organization takes steps to ensure confidentiality, 3) it would be "impracticable" to obtain
consent, and 4) the organization gives prior notice to the Privacy Commissioner. The
Commissioner has not discussed the scope of this exemption, but clearly it offers some
possibilities for pharmaceutical and device manufacturers in Canada. On the one hand, it
is unlikely that the classic research and development activities of a pharmaceutical or
device manufacturer (e.g., research and development of a new chemical entity through
clinical trials in order to prepare and submit an application for marketing authorization)
would constitute "scholarly study or research" within the scope of this exception. For
example, it will rarely be "impracticable" to obtain consent from clinical trial participants. 8
On the other hand, however, some medical research (e.g., retrospective epidemiological
research unrelated to a particular product and conducted by researches at a university
medical center) might fall within the exception. There may be room to argue for application
of the exception at points along the spectrum between these examples.
-' C.R.C. 2001-7(e), Regulations Specifying Publicly Available Information.
55 PIPEDA § 2(1).
56 Id. § 4(2).
51 Id. § 7(2)(c).
58 This exception could alleviate some of the burden imposed on pharmaceutical and device
manufacturers by the supposed retroactivity of the Act. In some cases a company might conclude it
is difficult or impossible to contact data subjects from long concluded trials in order to obtain consent
to transfer. It may be possible to argue for application of this exception in that situation.
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Provincial legislation providing "substantially similar" protection to personal infor-
mation preempts the Act.59 To date, only Quebec has implemented comprehensive pri-
vacy legislation. The Quebec statute is discussed in section IV of this article.
B. Obligations of the Organization
An organization subject to PIPEDA must identify the purpose(s) for which it collects,
uses, and discloses personal information. It may not collect, use, or disclose that infor-
mation except to fulfill those stated purposes, and may do so only with the consent of
the data subject. It must keep the information as accurate and current as necessary to
ensure that incorrect information is not used to make a decision about the individual.
The organization is also subject to administrative requirements designed to protect
personal information in its possession.
1. Identifying Purposes for Collection, Retention, Use, and Disclosure
Before collecting personal information, an organization must identify the purpose(s)
for which the information will be used. An organization may collect personal information
only for a purpose that a reasonable person would consider "appropriate."' Both the
amount and the type of information collected must be "limited to that which is necessary
to fulfill the purposes identified." 6 1 Any information that is no longer needed to fulfill a
stated purpose should be "destroyed, erased or made anonymous. 62
The organization may only make uses and disclosures of personal information that
are consistent with its stated purpose. Although this would seem to suggest broadly
worded consents are more effective, consent to a purpose stated without adequate
precision may be deemed invalid.63 To determine whether a use is consistent with a
stated purpose, the organization must ask whether a reasonable person would consider
the use reasonably related to the purpose consented to.64
If an organization wishes to use or disclose already-collected information for a pur-
pose other than the purpose for which it was originally collected, the organization must
inform the individual subject and secure his consent. Also, an organization collecting
information must do so "by fair and lawful means. '65 Thus, it may not mislead or deceive
individuals about the purpose for which it is collecting information.
2. Consent
Unless one of the express exceptions applies, as of January 1, 2002, no private sector
organization subject to PIPEDA may disclose for consideration information in one prov-
ince that was collected in another, without the data subject's consent. After January 1,
2004, no private sector organization covered under the law will be permitted to collect,
use, or disclose personal information about someone without his consent.66 Normally,
59 PIPEDA § 26(2)(b).
I d. § 5(3); GUIDE FOR BUSINESSES, supra note 38, at 6.
61 PIPEDA Schedule 1, § 4.4.1.
62 Id. Schedule 1, § 4.5.3.
61 GutIo* FOR BUSINESSES, supra note 38, at 8.
6 Id. at 6.
6' PIPEDA Schedule 1, § 4.4.2.
6 George Radwanski, Privacy Commissioner of Canada, ePrivacy-Transforming Customer Privacy
into a Catalyst for Your Business, Address to the eCustomer World 2001 Conference (Oct. 9, 2001),
available at http://www.privcom.gc.ca/speech/0205_ a_011009_e.asp (last visited June 19, 2002).
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the organization must obtain consent from the individual whose personal information is
being collected. If, however, the individual is seriously ill, is mentally incapacitated, or is
a minor, the organization may obtain consent from a legal guardian or a person having
power of attorney."
a. Meaningful Consent Required
An organization must obtain an individual's meaningful consent to collect, use, or
disclose his personal information. For his consent to be meaningful, the individual must
understand how the organization will use his personal information.' The organization
must therefore "make a reasonable effort" to advise the individual of the purposes of the
data collection in a manner that ensures "the individual can reasonably understand how
the information will be used or disclosed."'69 According to the Privacy Commissioner,
consent clauses should 1) be easy to find, 2) use clear and straightforward language, 3)
not use blanket categories for purposes, uses and disclosures, and 4) be as specific as
possible about which organizations handle the information.'0
b. Freely Given Consent
Consent must be freely given. The organization may not make consent a condition of
supplying a product or service "beyond that required to fulfill the explicitly specified,
and legitimate purposes" for which it is collecting, using, or disclosing the information
in the first instance.7 Although the Privacy Commissioner has offered no guidance on
this point, it is likely he would say a physician may not condition medical treatment on
the patient's willingness to have his medical information sold to a pharmaceutical manu-
facturer. On the other hand, a pharmaceutical company or medical researcher presum-
ably could condition participation in a clinical trial on the subject's willingness to have
his data analyzed and included in an application for marketing authorization. The Pri-
vacy Commissioner has not addressed these questions, however, or the related ques-
tion whether participation in a trial could be subject to a patient's willingness to waive
his right of access to his data.
c. Scope of Consent
An organization may not construe consent to use personal information for a given
purpose beyond "the reasonable expectations of the individual."7 For example, an
individual would reasonably expect that a publisher will use name and address informa-
tion collected from new magazine subscribers for mailing and billing purposes and to
solicit renewals.73 An individual would not reasonably expect, however, that a healthcare
provider, collecting personal information from persons seeking medical care, will give
that information to a company selling healthcare products.74 In this case, the healthcare
provider would need to identify the second purpose and seek the individual's separate
consent.
67 GUIE FOR BUSlNESSES, supra note 38, at 9.
68 Id.
69 PIPEDA Schedule 1, § 4.3.2.
70 GuIDE FOR BusmiitssES, supra note 38, at 9.
71 PIPEDA Schedule 1, § 4.3.3.
72 Id. Schedule 1, § 4.3.5.
11 Id. Schedule 1, § 4.3.4.
" Id. Schedule 1, § 4.3.5.
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d. Means of Expressing Consent
The statute permits implied as well as express consent, and oral as well as written
consent.71 It does not require any particular type of consent in any particular situation,
and the Privacy Commissioner has explained that the type of consent required depends
on the nature of the information collected and the circumstances under which consent
is given.7 6 An organization should seek express consent (i.e., "opt-in" consent), 77 either
oral or written, 78 for information considered sensitive.7 9 The statute does not define
"sensitive data" and the Privacy Commissioner has not offered a definition. The phrase
likely includes all personal health information. Implied consent (i.e., "opt-out" consent)
may be sufficient for less sensitive data. 0 The current Privacy Commissioner, however,
does not favor "opt-out" consent,"1 and a case pending before his office may provide an
opportunity for him to articulate the situations, if any, where opt-out is permissible. 2
e. Withdrawal of Consent
An individual may withdraw his consent for an organization's collection, use, or
disclosure of his personal information at any time, "subject to legal or contractual
restrictions and reasonable notice." 3 If there are consequences to withdrawing con-
sent, the organization must explain them when it secures the data subject's initial con-
sent.' It appears that a clinical trial informed consent form could state that, although a
trial participant may withdraw from the trial, any data collected prior to withdrawal will
continue to be used.
f. Exceptions to the Consent Requirement
Although consent is the cornerstone of the Act's privacy protections, it is not abso-
lute. The Act provides specific exceptions from the consent requirement for the collec-
tion, use, and disclosure of information. Some of these exceptions are of particular
importance to pharmaceutical and device manufacturers.
First, an organization need not obtain an individual's consent to collect personal
information if the collection is clearly in the interests of the individual and the organiza-
tion cannot obtain consent in a timely way. 5
7 Id. Schedule 1, § 4.3.7.
76 GUIDE FOR BusINEssEs, supra note 38, at 9.
77 The statute does not explicitly equate express consent with "opt-in" consent, or implied
consent with "opt-out" consent. The writings of the Privacy Commissioner are, however, consistent
with this reading.
78 PIPEDA Schedule I, § 4.3.7; GUIDE FOR BUSINESSES, supra note 38, at 9.
7 PIPEDA Schedule 1, § 4.3.6; Radwanski, Address to the eCustomer World 2001 Conference,
supra note 66.
80 PIPEDA Schedule 1, § 4.3.6.
S Radwanski, Address to the eCustomer World 2001 Conference, supra note 66 ("Most privacy
advocates, myself included, consider opt-out to be pretty poor privacy .... I suggest that you be
cautious about what's known as 'opt-out' consent.").
82 Public Interest Advocacy Center, Complaint re: Inadequate Approaches to Opt-Out Consent
(Oct. 16, 2001), available at http://www.piac.ca/Complaint%20to%20PCC-LH.htm (last visited
June 19, 2002) (charging that implied consent policies are insufficient to permit transfers for
secondary marketing purposes).
83 PIPEDA Schedule 1, § 4.3.8.
1 CSA WORKBOOK, supra note 39, at 11.
11 PIPEDA § 7(1). Other exceptions to consent for collection of personal information apply if:
1) the collection is reasonably related to a criminal investigation and the individual's knowledge or
consent would compromise the availability or the accuracy of the information; and 2) the collection
is solely for journalistic, artistic, or literary purposes.
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Second, an organization need not obtain an individual's consent to use personal
information if the information is used to respond to an emergency threatening the life,
health, or security of an individual, or if the information is necessary for statistical,
scholarly, or research purposes and obtaining consent for the use is impracticable. In
such cases, the organization must ensure the information's confidentiality and give
prior notice of the use to the Privacy Commissioner. 6
Third, an organization need not obtain an individual's consent to disclose personal
information if the disclosure is required by law. It may be possible to argue that the
requirements of foreign law (e.g., event reporting requirements) trigger this exception.
As noted earlier, an organization need not obtain an individual's consent to disclose
personal information if the information is necessary for statistical, scholarly, or research
purposes and obtaining consent for the disclosure is impracticable. In this case, the
organization must give prior notice of the disclosure to the Privacy Commissioner.
Further, an organization need not obtain an individual's consent to disclose personal
information if the disclosure is made at the earlier of either a) 100 years after the organi-
zation collected the personal information, or b) twenty-five years after the death of the
subject of the personal information. Finally, an organization need not obtain an individual's
consent to disclose personal information if the disclosure is made to a person respond-
ing to an emergency threatening the life, health, or security of an individual. If the
subject of the disclosed personal information is alive, the organization must promptly
inform that person of the disclosure.87
g. Retroactive Application
The Privacy Commissioner has stated that personal information collected prior to the
Act's effective date is subject to its provisions."8 In his view, once the Act applies to an
organization, the organization may not use or disclose information within its posses-
sion-no matter when it was collected-without legally valid consent. This retroactive
effect is not apparent on the face of the statute.
The Privacy Commissioner could take the position, therefore, that identifiable data
collected in a clinical trial prior to January 2002 may not be disclosed for consideration
by an organization subject to PIPEDA unless the data subjects provided opt-in consent
that complied with PIPEDA. He could similarly conclude that identifiable data collected
prior to January 2004 may not be used unless it was collected in compliance with PIPEDA.
At a minimum, this suggests the need to ensure on a prospective bases that all data
collected are collected in conformity with PIPEDA. Companies also should review data
within their possession to determine whether subjects adequately consented. As noted
above, the exception for data necessary for research purposes, where obtaining con-
sent is impracticable, could alleviate some of the burden posed by the Act's retroactive
application.89
86 Id. § 7(2). In addition, if, in the course of its activities, an organization determines that
personal information in its possession might reasonably be useful to a criminal investigation, an
organization need not obtain an individual's consent to use personal information.
17 Id. § 7(3). Other exceptions to consent for disclosure of personal information apply if: 1) the
disclosure is made to a barrister or solicitor representing the organization in the Province of Quebec;
2) the disclosure is for the purpose of collecting a debt owed by the individual to the organization; 3)
the disclosure is required to respond to a subpoena or warrant issued by a court; 4) the disclosure is
made to a government institution investigating criminal conduct or other security concerns; and 5)
the disclosure is made to an institution whose functions include the conservation of records of historic
or archival importance, and the disclosure is made for the purpose of such conservation.
88 GUIDE FOR BusINEssEs, supra note 38, at 8.
89 See supra note 58.
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3. Accuracy
An organization must keep personal information as accurate and current as neces-
sary "to minimize the possibility that inappropriate information may be used to make a
decision about the individual."" The use of incomplete, wrong, or obsolete information
for decisionmaking can result in "significant harm to the individual and lost opportuni-
ties for the company."'" Accordingly, if an organization uses personal information on an
ongoing basis or routinely shares information with third parties, it should ensure the
information's accuracy. Drafters of the Model Code emphasized the importance of"up-
dating, amending, or correcting" erroneous information "as expeditiously as possible."92
At the same time, the Act specifically prohibits an organization from routinely updating
personal information "unless such a process is necessary to fulfill the purposes for
which the information was collected."93 Organizations will in all likelihood need to re-
think their data retention policies, including why they update certain data, and how they
purge data that are no longer needed.
4. Administrative Requirements
The Act imposes various administrative obligations on organizations subject to its
provisions.
First, an organization must develop a privacy policy and procedures that address
each of the obligations imposed by PIPEDA.94 These documents must state the
organization's purpose for collecting data, prescribe methods for securing consent,
impose limits on data use and disclosure, ensure accuracy and security, provide for
individual access, and provide a framework for responding to inquiries and complaints.
Second, to oversee implementation of its privacy policy and practices, the organiza-
tion must designate an individual or individuals responsible for the organization's com-
pliance with the Act. The Office of the Privacy Commissioner urges organizations to
assign oversight responsibilities to management employees, preferably senior execu-
tives.95
Third, an organization must make public its privacy policies and procedures and
identify the persons responsible for implementing them. It must identify the type of
personal information it holds and the purpose(s) for which it does so, and it must explain
how the data subjects may access this information. It must describe the information that
is made available to other organizations, including subsidiaries,96 and, if requested, it
must provide a list of any organizations to which it has disclosed such information.97
Fourth, an organization must adopt security safeguards commensurate with the sen-
sitivity of the personal information in its possession.98 Such measures should address
90 PIPEDA Schedule 1, § 4.6.1.
'l CSA WORKBOOK, supra note 39, at 18.
92 Id. Because the organization continues to be responsible for personal information until it is
destroyed, the organization is likely obligated to inform third party recipients of that information of
any changes.
9 PIPEDA Schedule 1, § 4.6.2.
9 Id. Schedule 1, § 4.1.4.
9 Anne Rooke, The Role of the Federal Privacy Commissioner, Presentation to Ottawa Confer-
ence on E-Commerce and Privacy: Implementing the New Law in the Public and Private Sector (Feb.
21, 2000), available at http://www.pivcom.gc.ca/speech/02_05-a_000221_2_e.asp (last visited June
19, 2002).
96 PIPEDA Schedule 1, § 4.8.2; GUIDE FOR BUSINESSES, supra note 38, at 15.
97 GUIDE FOR BusINEssEs, supra note 38, at 15.
98 PIPEDA Schedule I, § 4.7.2.
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the manner in which the information is stored and should protect against loss or theft as
well as unauthorized access, disclosure, copying, use, or modification of the data.99
5. Transfers to Third Parties
An organization is responsible for personal information "under its control."1 00 Al-
though the Act does not define when information is under the control of an organiza-
tion, the Act's requirements logically apply to personal information in the organization's
possession or custody.'°' They also apply to information the organization transfers to
third parties for processing.0 2 This suggests that an organization may be liable for any
privacy offenses those parties commit. When contracting with third parties to handle
personal information, an organization therefore should include provisions to ensure
adequate privacy protection.0 3 For example, the contract should ensure that the third
party: 1) names a person to oversee privacy matters related to the contract; 2) limits use
of the personal information to the purposes specified by the contract; 3) limits disclo-
sure of the personal information to what is authorized by the collecting organization or
required by law; 4) refers data subjects looking to access the personal information to the
collecting organization; 5) returns or disposes of the personal information after comple-
tion of the contract; 6) uses appropriate security measures to protect the personal
information; and 7) allows the collecting organization to audit the third party's compli-
ance with the contract as necessary" Inclusion of these provisions in a contract
probably will not relieve the collecting organization from responsibility under the stat-
ute. It may provide some recourse, however, against a third party that commits a privacy
offense.
The statute does not address transfers of personal information to parties outside of
Canada and the Privacy Commissioner has not addressed the subject. In light of the
Privacy Commissioner's view, however, that 1) the Act applies to conduct outside
Canada, 0 5 and 2) an organization is responsible for the acts of its agents, an organiza-
tion inside Canada should expect to answer to the Privacy Commissioner if a recipient in
the United States fails to comply with the PIPEDA standards.
C. Individual Rights Under PIPEDA
A data subject has several rights enumerated in PIPEDA. First, subject to several
significant exceptions, he has the right to access the personal information about him
that an organization holds. Second, subject again to several exceptions, he has the right
to demand that inaccuracies be corrected. Third, he has the right to complain about the
organization's privacy practices either to the organization or to the Privacy Commis-
sioner, and the right to take his grievance to federal court. This section addresses the
" Id. Schedule 1, § 4.7.1.
'01 Id. Schedule 1, § 4.1.
I0J Id. Schedule 1, § 4.1.3.
02 Id. (requiring organizations to "use contractual or other means to provide a comparable level
of protection while the information is being processed by a third party").
103 Id.
o GUIDE FOR BUSImSSES, supra note 38, at 7.
"I George Radwanski, Privacy Commissioner of Canada, Address to the Third Annual BNA
Public Policy Forum: International eCommerce and Internet Regulation (Nov. 14, 2001), available
at http://www.privcom.gc.ca/speech/02-05_a_011114_e.asp (last visited June 19, 2002) (noting
that the effect of the Act "won't be limited by the Canada-U.S. border, because it's not just Canadians
who have rights under the act, but anyone whose personal information is collected, used, or disclosed
by an organization subject to the Act").
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first two rights. The third is addressed in Part III of the article, which discusses enforce-
ment of the Act.
1. Access
If asked by an individual, an organization must accurately report what personal infor-
mation, if any, it holds about that person."° It must also provide assistance to any indi-
vidual who needs help preparing a written request.17 The organization also must provide
an accounting of "the use that has been made or is being made of this information,"'08 and
"third parties to which [the organization] has [or may have] disclosed personal informa-
tion about an individual." 1 09 The organization must respond to requests "with due dili-
gence and in any case not later than thirty days after receipt,"" 10 and "at minimal or no cost
to the individual."' I Furthermore, it must provide the information "in a form that is gener-
ally understandable," that is, without unexplained codes or abbreviations."I2
There are significant exceptions to the access requirement. First, the organization
may choose to make "sensitive medical information" available only "through a medical
practitioner.""' 3 Second, the organization may deny individuals access to information
that is prohibitively expensive to provide, that contains references to other individuals,
or that is privileged for legal, security, or commercial proprietary reasons. The scope of
the exception for "commercial proprietary reasons" is not clear. It could extend to some
information generated in a clinical trial or generated in the course of research on a
biological sample. If an organization denies access to personal information, it must
provide reasons for the denial upon request by the individual.
2. Correction
If an individual believes that personal information in an organization's records is
inaccurate, he may ask the organization to correct it.' "4 The individual must make this
request in writing and attach documents demonstrating the data error."5 If it agrees with
the request, the organization must promptly amend its records. It may, however, dispute
the request and leave its records unchanged. In that case, the individual may require the
organization to attach a statement to his file noting the disagreement. The organization
must pass this statement on if it discloses the data to a third party.
1 6
106 The request must be made in writing, see PIPEDA § 8(1), and must include enough detail to
allow the organization to identify the desired data, e.g., it should include dates, account numbers, and
the names and positions the person may have dealt with at the organization. See OFFCE OF THE PRIVACY
COMMISSIONER OF CANADA, YOUR PRIVACY RIGHTS: A GUIDE FOR CANADIANS (2001) [hereinafter GUIDE FOR
CANADIANS].
107 GUIDE FOR BUSINESSES, supra note 38, at 15.
108 PIPEDA Schedule 1, § 4.9.1.
109 Id. Schedule 1, § 4.9.3.
" Id. § 8(3). The organization may extend this time limit for a maximum of thirty additional
days if "meeting the time limit would unreasonably interfere with the activities of the organization,"
or "the time required to undertake any consultations necessary to respond to the request would make
the time limit impracticable to meet." Id. § 8(4)(a). Alternatively, the organization may extend the
time limit for whatever period "is necessary to be able to convert the personal information into an
alternative format." Id. § 8(4)(b). in either case, the organization must give notice of the extension
to the individual within the original thirty-day period. Id.
" Id. Schedule 1, § 4.9.4.
112 Id.
113 id. Schedule 1, § 4.9.1.
114 GUIDE FOR CANADIANS, supra note 106.
115 Id.
116 Id.
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III. ENFORCEMENT OF THE ACT
The statute requires every organization under its jurisdiction to establish a proce-
dure for responding to complaints. A data subject may complain directly to the orga-
nization about its collection, use, or disclosure of his data. In addition, or in the alterna-
tive, a data subject may file a written complaint directly with the Privacy Commissioner.
The Act allows recourse to the courts after review by the Privacy Commissioner. The
Act also allows the Privacy Commissioner to act independently to audit the privacy
policies and procedures of an organization suspected of committing violations.
A. Complaint to the Organization
An organization must have "easily accessible and simple to use" procedures in place
for receiving and responding to complaints from individual data subjects respecting the
organization's collection, use, or disclosure of personal information. "7 An organization
must advise data subjects of available "avenues of recourse," including the organization's
"relevant complaint procedures,""' 8 any applicable industry association procedures,
and the statutory provisions for filing complaints directly with the Privacy Commis-
sioner. If an organization receives a complaint, it must investigate. "9 The organization
must take appropriate measures, including amending its privacy policies and practices,
if it finds the complaint is justified. 20
The Privacy Commissioner offers several recommendations with respect to the han-
dling of internal investigations. For example, he recommends opening a clear channel of
communication with the individual to acknowledge receipt of the complaint, to clarify
the nature of the complaint, and to provide prompt notification of the outcome when
reached. He recommends assigning the investigation to a person with access to both
the relevant records and the employees who handled the personal information. He also
recommends keeping a record of decisions following investigations to "ensure consis-
tency in applying the Act."' 2'
B. Individual Complaints Filed With the Privacy Commissioner
An individual data subject may file a written complaint directly with the Privacy
Commissioner. The Commissioner will review the complaint and, if "satisfied that there
are reasonable grounds" to do so, may initiate an investigation. 122
The Commissioner's investigative powers under the Act are broad. While pursuing
an investigation, the Commissioner has the authority to "summon and enforce the
appearance of persons before the Commissioner and compel them to give oral or written
evidence on oath and to produce any records and things that the Commissioner consid-
ers necessary to investigate the complaint, in the same manner and to the same extent as
a superior court of record." In other words, the Commissioner has subpoena power. He
may also "administer oaths" and "receive and accept any evidence and other informa-
tion, whether on oath, by affidavit or otherwise, that the Commissioner sees fit." The
Commissioner may review this evidence "whether or not it is or would be admissible in
117 PIPEDA Schedule 1, § 4.10.2.
"' Id. Schedule 1, § 4.10.3.
lI Id. Schedule 1, § 4.10.4.
10 Id.
121 GUIDE FOR BusINEssEs, supra note 38, at 16.
122 PIPEDA § 11(2).
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a court of law." The Commissioner or his staff may "enter any premises, other than a
dwelling-house, occupied by an organization on satisfying any security requirements
of the organization relating to the premises." They may question or converse with "any
person in any premises" entered. Finally, they may "examine or obtain copies of or
extracts from records found" on the premises if the records "contain any matter relevant
to the investigation."'23 If in the course of an investigation the Commissioner finds
evidence of an unrelated crime, he may report it to the appropriate authorities. 24
The Privacy Commissioner has expressed a reluctance to use these powers, and in
November 2001, his Office reported that all complaints to date had been "resolved
without having to use these formal investigative powers, because voluntary coopera-
tion with investigations has been forthcoming."'2 The Privacy Commissioner states
that the focus of his staff is "to seek whenever possible to resolve disputes through
investigation, persuasion, mediation, and conciliation."' 26
The Commissioner will prepare a report of findings and recommendations from his
investigation. He may then try to mediate the controversy or resolve the complaint through
some other method for dispute resolution. Although the Commissioner may not issue
binding orders, he may make his findings public.' 27 He may also include the audit report in
his annual report to Parliament.'11 Alternatively, he may seek remedies in court, advise the
complainant to "exhaust grievance or review procedures otherwise reasonably available,"
or advise him to pursue the complaint under a law other than the Act.2 9
It is a criminal offense to obstruct the Commissioner during an investigation or au-
dit.130 It is a criminal offense to knowingly dispose of information that is the subject of a
request by an individual.' Anyone who obstructs the Commissioner or who destroys
records before all recourse is exhausted is guilty of an offense and may be liable for fines
of up to $100,000.132 It is also a criminal offense for an employer to take retaliatory action
against employees who report a violation of the Act.'33 Directors, officers, and employ-
ees may be made personally liable for fines. 134
C. Individual Complaints Filed With the Federal Court
If not satisfied by the remedies afforded by the Commissioner, a complainant may
take his grievance to federal court. A reviewing court might determine, for example,
whether a company had properly identified and documented the purposes for which
data were being collected,'135 or whether it had used or disclosed data for purposes other
than those for which it the data were collected.136 The Commissioner may represent the
complainant at the hearing or, with leave of the court, appear on his own behalf.37 If the
123 Id. § 12(1).
124 Id. § 20(5).
125 About the Office of the Privacy Commissioner, supra note 10.
26 GUIDE FOR BUSINESSES, supra note 38, at 19.
127 George Radwanski, Privacy Commissioner of Canada, Privacy and Health Information,
Address to the Canadian Medical Association (Nov. 24, 2000) (noting that the Commissioner is "free
to make privacy abuses known to the media. The court of public opinion can be a powerful force.").
128 PIPEDA § 19(2).
129 Id. § 13(2).
130 Id. § 28.
131 Id.
132 Id. § 28(b).
"33 Id. § 27.1.
,14 Id. § 28 (holding "[e]very person who knowingly contravenes" the Act responsible).
13. PIPEDA Schedule 1, § 4.2.
136 Id. Schedule 1, § 4.5.
131 PIPEDA § 15(c).
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court finds in favor of the complainant, it may order the organization to correct its
practices in order to comply with the statute, order the organization to publish a notice
of any action taken or proposed to be taken to correct its practices, and award damages
to the complainant, including unlimited damages for any humiliation that the complain-
ant has suffered. 3 '
D. Audits
The Commissioner may "on reasonable notice" and "at any reasonable time," audit
the personal information management practices of an organization if the Commissioner
has "reasonable grounds" to believe that the organization is contravening a provision
of the statute.'39 A complaint from a competitor or public interest group could presum-
ably provide these "reasonable grounds." The powers available to the Commissioner
during an audit are the same as his investigative powers.'" If in the course of an audit
the Commissioner finds evidence of an unrelated crime, he may report it to the appropri-
ate authorities. 4' After an audit, the Commissioner must file a report with the organiza-
tion, summarizing his findings and offering recommendations for revising privacy poli-
cies and procedures to ensure compliance with the Act.
IV. THE RELATIONSHIP BETWEEN PIPEDA AND OTHER PRIVACY LAWS
A. Legislation in Canada
1. The Federal Privacy Act
PIPEDA works in conjunction with the Federal Privacy Act. The Privacy Act applies
to specific government institutions and imposes requirements of notice, choice, and
access on their handling of personal information. When fully in force, PIPEDA will
apply similar principles to the commercial sector. The two regimes are not, however,
identical. For example, the Privacy Act does not require consent to collect personal
information. Instead it requires that collected information relate directly to an activity of
the collecting institution. 42 This may complicate transfers of personal health informa-
tion from the public health sector to the private sector.
2. Provincial Law
Prior to enactment of PIPEDA, several provinces had enacted sector-specific privacy
laws. Two such statutes are Manitoba's Personal Health Information Act and
Saskatchewan's Health Information Protection Act.'43 Several more provinces have
enacted sector-specific privacy laws since PIPEDA. In April 2001, for example, Alberta
enacted a Health Information Act regulating information handled by healthcare provid-
ers.'" Thus, an organization operating in a province that has enacted sector-specific
I ld. § 16; GUIDE FOR BUSINESSES, supra note 38, at 24.
139 PIPEDA § 18(1).
40 Id. § 18()(a)-(f).
141 Id. § 20(5).
141 Privacy Act § 4, Collection, Retention and Disposal of Personal Information.
W See generally Manitoba Access and Privacy Division, available at http://
www.ombudsman.mb.ca; Saskatchewan Health, available at http://www.health.gov.sk.ca (last visited
June 19, 2002).
'" See generally Alberta Health and Wellness, available at http://www.health.gov.ab.ca (last visited
June 19, 2002).
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legislation may need to consider both the federal PIPEDA and provincial health privacy
law.
Only one province has enacted comprehensive privacy legislation. In 1994, Quebec
enacted the Personal Information Protection Act (PIPA), 145 which, like the federal Act,
governs the collection, retention, use, and disclosure of personal information. PIPA
defines personal information as "any information which relates to a natural person and
allows that person to be identified,"' 46 and it allows collection, use, or communication of
such information only if the data subject consents and only for a specifically-identified
purpose. Largely in deference to the existing Quebec law, PIPEDA includes a provision
that
the Governor in Council may, by order... if satisfied that legislation of a province
that is substantially similar to this Part applies to an organization, a class of
organizations, an activity, or a class of activities, exempt the organization, activ-
ity, or class from the application of this Part in respect of the collection, use, or
disclosure of personal information that occurs within that province." 1
47
The legislative history makes it clear that Parliament intended this to reach the Que-
bec statute, 4 ' and the Privacy Commissioner has stated repeatedly that the government
has concluded Quebec meets the "substantially similar" standard.4 9
B. Foreign Law
Organizations operating in the European Union and the United States, in addition to
Canada, also will need to take into account the European Community's Data Protection
Directive' and the regulations promulgated by DHHS under HIPAA.'5'
The EU, U.S., and Canadian laws reflect what have now become generally-accepted
principles of privacy law-that data subjects should be told of the uses that will be
made of their data (notice), that they will be asked to consent to these uses or will be
given the choice to refuse those uses (choice and consent), that they will be allowed to
see and to correct the data that are held (access), that organizations must safeguard
personal data from unauthorized uses and accidental disclosures (security), and that
organizations are accountable for privacy violations (accountability).
A comprehensive and detailed comparison of PIPEDA with the Directive and the
HIPAA regulations is beyond the scope of this article. The schemes differ, however, in
several key respects. For example, the EU distinguishes between sensitive data and
nonsensitive data, requiring opt-in consent for collection, use, and disclosure of sensi-
145 R.S.Q. Ch. P-39.1, An Act Respecting the Protection of Personal Information in the Private
Sector.
146 Id. Div. 1, § 2.
147 PIPEDA § 26(2)(b).
118 Phillips, 1999 Annual Report of the Privacy Commissioner, supra note 3 ("The federal
government has stated that Quebec will be exempt from the federal law because Quebec's 1994
legislation covers the private sector and is substantially similar to Part I.").
41 See, e.g., id.; George Radwanski, Privacy Commissioner of Canada, Address to the Canadian
Institute (Dec. 6, 2000), available at http://www.privcom.gc.ca/speech/02- 05_a_001206_e.asp
(last visited June 19, 2002) ("The federal government has already stated publicly that Quebec's law is
substantially similar so, in all likelihood, that exemption will be forthcoming.").
1-0 Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on
the protection of individuals with regard to the processing of personal data and on the free movement
of such data. 1995 O.J. (L 281) 31.
'I" Pub L. No. 104-191, § 264(c)(1); see 65 Fed. Reg. 82,462 (Dec. 28, 2000).
224 VOL. 57
2002 AN OVERVIEW OF CANADIAN PRIVACY LAW 225
tive data. While the Canadian legislation acknowledges the category of sensitive data,
it does not define "sensitive" and does not expressly require opt-in choice. To give
another example, the preamble to the DHHS regulations addresses exemption from con-
sent for the reporting of adverse events to FDA. Although Canadian law provides an
exception for disclosures required by law, the Privacy Commissioner has not offered any
interpretation of the scope of this provision. Also, the DHHS regulations include a list
of eighteen identifiers of personal health information. If, after having stripped the infor-
mation of these identifiers, a covered entity has "no actual knowledge" that the informa-
tion could be used to identify a subject, the information is "de-identified" and, therefore,
is outside the scope of the DHHS regulations.'52 In contrast, neither the Directive nor
PIPEDA provides such a list. Individual EU Member States and the Canadian Privacy
Commissioner may take differing views on whether exclusion of a particular element
renders the data subject nonidentifiable.
Although the schemes differ, we have not identified any instance in which a com-
pany operating in the United States, the EU, or Canada, or transferring health data from
one jurisdiction to another, would face conflicting obligations. Companies operating in
Canada and the EU may take comfort also in a recent decision of the European Commis-
sioner. In addition to regulating the processing of personal data within Europe, the
Directive prohibits the transfer of data outside the European Economic Area unless the
data will receive "adequate" protection in the importing country.'53 The Canadian
Parliament's enactment of PIPEDA was prompted by a desire to satisfy the "adequate
protection" standard and in December 2001, the European Commission found that it
complied.5 4 Accordingly, the EU now permits transfers between member states and
organizations in Canada subject to the Act's provisions. The finding of adequacy sug-
gests it should be feasible for a multinational corporation to derive a policy that satisfies
both regimes. (The U.S. health privacy regulations do not address transfer to foreign
jurisdictions.) Nevertheless, pharmaceutical and device manufacturers operating in
multiple jurisdictions should review these frameworks more closely to confirm the ab-
sence of conflict. In the EU, individual Member State laws also should be taken into
account. Similarly, individual U.S. state privacy laws will come into play, and Canadian
provincial legislation could apply.
V. EFFECTIVE DATE AND TRANSITION PROVISIONS
From January 1, 2001, to January 1, 2002, PIPEDA applied to works, undertakings,
and businesses within the legislative authority of Parliament. Examples of such works
include interprovincial or international transportation by land or water, airports, aircraft
or airlines, telecommunications, radio and television broadcasting, banks, grain eleva-
tors, nuclear facilities, and offshore drilling operations. The Act also applied to the
entire commercial private sector in the Yukon, Northwest Territories, and Nunavut be-
cause all local businesses in the territories are considered federal works, undertakings,
and businesses and are under the jurisdiction of the federal Parliament. 5 In addition,
the Act applied to personal information disclosed for consideration outside the prov-
ince in which it was collected. During this first year of its operation, however, the Act did
not apply to personal health information. 5 6
52 45 C.F.R. § 164.514(b)(2).
153 95/46/EC, Art. 25.
'u Commission Decision 2002/02/EC of 20 December 2001, Art. 1.
15OFFICE OF THE PRIVACY COMMISSIONER OF CANADA, FEATURE: CANADA'S PRIVACY LAW AND THE NoRTH (June
1I, 2001).
156 PIPEDA § 30(1.1), (2.1).
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As of January 1, 2002, the Act also applies to personal health information collected,
used, or disclosed by these organizations and to personal health information disclosed
for consideration outside the province in which it was collected. After January 1, 2004,
the Act will apply to the collection, use, and disclosure of personal information, includ-
ing personal health information, by any organization in the course of commercial activ-
ity within a province. It also will apply to all personal information, including personal
health information, in all interprovincial and international transactions by all organiza-
tions subject to the Act in the course of commercial activities.
VI. CONCLUSION
The Privacy Commissioner has thus far demonstrated his willingness to work with
organizations to resolve privacy disputes fairly and in a manner that takes into account
business concerns. But organizations must be wary of the consequences that might
flow from a failure to follow the requirements or even recommendations of the new law.
These consequences include considerable adverse publicity and apparently unlimited
money damages. Particularly in light of the apparent retroactive nature of the statute,
pharmaceutical and device manufacturers that collect, use, or disclose personal infor-
mation in Canada, or that intend to do so, should undertake now 1) to ensure that all
collection, use, and disclosure henceforth complies with PIPEDA, and 2) to take stock of
the impact of the statute on already-collected data that may need to be used or disclosed
after the transition period ends. Companies that operate in Canada, the EU, and the
United States will need to take into account multiple legal frameworks that overlap, but
are not identical.
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